Trial Profile
A Phase I, Open-Label Study to Assess the Effect of Escalating Doses of Cyclophosphamide on the Engraftment of SB-728-T in Aviremic HIV-Infected Subjects on HAART
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs SB 728 T (Primary) ; Cyclophosphamide
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Sangamo Therapeutics
- 06 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
- 02 May 2016 Data from cohort 3 expected in the second half of 2016, according to a Sangamo BioSciences media release.